-+ 0.00%
-+ 0.00%
-+ 0.00%

BRISTOL-MYERS SQUIBB COMPANY - SERIOUS ADVERSE REACTIONS IN 58.3% AND FATAL IN 4.9% OF ZENBEXUS PATIENTS

Reuters·10/08/2026 10:59:00

Please log in to view news